STOCKHOLM--(BUSINESS WIRE)--SciBase (STO:SCIB)
As a result of his appointment as Head of Investment at Karolinska Development, Viktor Drvota has resigned from SciBase’s Board of Directors. Alternate director Andreas Pennervall will take his place.
Viktor Drvota moves on to Karolinska Development having been Head of Life Science Venture at SEB Venture Capital. Viktor has been a member of SciBase’s board since 2005. Andreas Pennervall has been an alternate director in SciBase’s board since 2013.
Information on Viktor Drvota’s withdrawal has been submitted to the Swedish Companies Registration Office on January 29th.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and is awaiting FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”). Avanza is the certified advisor. Further information is available on www.scibase.com.
SciBase Holding AB is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8 am on February 2, 2016.
This information was brought to you by Cision http://news.cision.com